Journal Article Summary
The article investigates how a specific genetic variant, known as Taq1A (rs1800497), influences the weight-loss response to the antiobesity medication naltrexone/bupropion (NB). This topic is significant because obesity is a widespread health issue, affecting over 40% of adults in the U.S., and responses to weight-loss medications can vary greatly among individuals. Understanding the genetic factors that affect these responses could lead to more personalized and effective obesity treatments.
In this pilot study, researchers analyzed data from 33 participants who were treated with NB, focusing on their genetic makeup and weight-loss outcomes over a period of 12 to 16 weeks. The study found that individuals with the A1+ genotype (those carrying at least one A allele) experienced a mean weight loss of 5.9%, significantly exceeding the clinically relevant threshold of 4%. In contrast, those with the A1− genotype (GG) had a mean weight loss of only 4.2%, indicating that the A1+ group responded better to the medication, with 86.7% achieving the target weight loss compared to 61.1% in the A1− group.
However, the study has limitations, including its small sample size and retrospective design, which may affect the reliability of the findings. Additionally, factors such as diet, physical activity, and medication adherence were not uniformly monitored, potentially influencing weight-loss results. Patients interested in this research should consult their healthcare providers to discuss their genetic background and the potential implications for weight-loss treatments, as well as to explore other personalized approaches to managing obesity.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Mullally Jamie A., Chung Wendy K., LeDuc Charles A., Reid Tirissa J., Febres Gerardo, Holleran Steven, Ramakrishnan Rajasekhar, Korner Judith. Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study. Diabetes, obesity & metabolism 2021. DOI: 10.1111/dom.14267. PMID: 33236485. PMCID: PMC8106923.
Featured Pill Pals Product
Bupropion 100 mg Sustained Release (SR) Tablets --- Generic For Wellbutrin SR --- Camber
Bupropion 100 mg Sustained Release (SR) Tablets — Generic For Wellbutrin SR — Camber is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
